MIM
LYEL icon

MetLife Investment Management’s Lyell Immunopharma LYEL Stock Holding History

MetLife Investment Management’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,814
Closed -$50.1K – 2838
2024
Q3 		$50.1K Sell
1,814
-2,459
-58% -$72.3K ﹤0.01% 2754
2024
Q2 		$124K Sell
4,273
-282
-6% -$13.4K ﹤0.01% 2492
2024
Q1 		$203K Sell
4,555
-50
-1% -$2.14K ﹤0.01% 2195
2023
Q4 		$179K Hold
4,605
– – ﹤0.01% 2296
2023
Q3 		$135K Hold
4,605
– – ﹤0.01% 2424
2023
Q2 		$293K Buy
4,605
+854
+23% +$47.3K ﹤0.01% 2029
2023
Q1 		$177K Sell
3,751
-874
-19% -$46.7K ﹤0.01% 2289
2022
Q4 		$321K Hold
4,625
– – ﹤0.01% 1928
2022
Q3 		$678K Hold
4,625
– – 0.01% 1417
2022
Q2 		$603K Buy
4,625
+399
+9% +$40.8K ﹤0.01% 1532
2022
Q1 		$427K Buy
+4,226
New +$512K ﹤0.01% 1867
2021
Q4 		– Sell
-516
Closed -$153K – 2529
2021
Q3 		$153K Buy
+516
New +$155K ﹤0.01% 2247

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

MetLife Investment Management's LYEL Position: Q4 2024 in Review

MetLife Investment Management sold out of Lyell Immunopharma (LYEL) in Q4 2024, closing a stake of 1,814 shares — an estimated $50.1K sold.

MetLife Investment Management first reported a position in LYEL in Q3 2021 and held it in 12 quarters. The position peaked at $678K in Q3 2022. 105 funds tracked by Wall St. Rank hold LYEL as of Q4 2024.

  • MetLife Investment Management reported no remaining Lyell Immunopharma position as of Q4 2024 after selling out during the quarter.
  • MetLife Investment Management sold 1,814 Lyell Immunopharma shares in Q4 2024, an estimated $50.1K.
  • MetLife Investment Management first reported a position in Lyell Immunopharma in Q3 2021 and held it in 12 quarters.
  • MetLife Investment Management's Lyell Immunopharma position peaked at $678K in Q3 2022.
  • 105 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q4 2024.

Based on MetLife Investment Management's 13F filing for Q4 2024, filed 13 Feb 2025.